trending Market Intelligence /marketintelligence/en/news-insights/trending/swt-5y8_bulroq9nz0prhw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

ProQR prices common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ProQR prices common stock offering

ProQR Therapeutics NV priced an underwritten public offering of 5,750,000 ordinary shares at $15.75 each.

The Netherlands-based biopharmaceutical company expects to raise gross proceeds of about $90.6 million through the offering, which is expected to close Sept. 11, subject to customary closing conditions.

Underwriters have a 30-day option to buy up to 862,500 additional ordinary shares at the offering price.

Citigroup, Evercore ISI and RBC Capital Markets are acting as joint book runners for the offering, with H.C. Wainwright & Co. and Chardan as co-managers. Kempen & Co. is acting as ProQR's European financial adviser for the offering.